DrugDashboards

Etravirine

Etravirine · ETRAVIRINE 200 mg/1 · Tablet · Oral · Carnegie Pharmaceuticals LLC

NDC 80005-0113-09 · 60 TABLET in 1 BOTTLE · ANDA · View full market →

The short version

7 companies supply this market — a reasonable cushion if one runs into trouble.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

All Part D pricing →

Matched to CMS's representative package for this drug (NDC 59676-0571-01) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.

ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of saleⓘ
$24.48per unit
middle half $24.47–$24.49 · 2 plans · Apr 1, 2026
Est. net of rebatesⓘ
≈ $24.48
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
0%of plans cover it
tier 1 · prior auth 0% · step therapy 0% · qty limit 100%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for etravirine (oral solid) in the next 90 days

sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill · avg $1,062.34 per prescription
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
ANDA215402
TE code
AB
Approval date
Apr 13, 2022
Patents / exclusivity
None on file

Shortage history

  • Planned discontinuation — Etravirine, Tablet, 100 mg (NDC 10147-0570-1)Apr 28, 2026
  • Planned discontinuation — Intelence, Tablet, 100 mg (NDC 59676-570-01)Apr 28, 2026

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Etravirine (Tablet)

LabelerStrengthFirst seenLast seen
Amneal Pharmaceuticals NY LLCETRAVIRINE 100 mg/1Jul 15, 2026Sep 2, 2026
Amneal Pharmaceuticals NY LLCETRAVIRINE 200 mg/1Jul 15, 2026Sep 2, 2026
Amneal Pharmaceuticals NY LLCETRAVIRINE 25 mg/1Jul 15, 2026Sep 2, 2026
AvKAREETRAVIRINE 200 mg/1Jul 15, 2026Sep 2, 2026
AvKAREETRAVIRINE 100 mg/1Jul 15, 2026Sep 2, 2026
Bionpharma Inc.ETRAVIRINE 200 mg/1Jul 15, 2026Sep 2, 2026
Bionpharma Inc.ETRAVIRINE 100 mg/1Jul 15, 2026Sep 2, 2026
Carnegie Pharmaceuticals LLCETRAVIRINE 200 mg/1Jul 15, 2026Sep 2, 2026
Carnegie Pharmaceuticals LLCETRAVIRINE 100 mg/1Jul 15, 2026Sep 2, 2026
Janssen Products LPETRAVIRINE 25 mg/1Jul 15, 2026Sep 2, 2026
Janssen Products LPETRAVIRINE 100 mg/1Jul 15, 2026Sep 2, 2026
Janssen Products LPETRAVIRINE 200 mg/1Jul 15, 2026Sep 2, 2026
Leading Pharma, LLCETRAVIRINE 200 mg/1Jul 15, 2026Sep 2, 2026
Leading Pharma, LLCETRAVIRINE 100 mg/1Jul 15, 2026Sep 2, 2026
Patriot PharmaceuticalsETRAVIRINE 200 mg/1Jul 15, 2026Sep 2, 2026
Patriot PharmaceuticalsETRAVIRINE 100 mg/1Jul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Etravirine — NDC 80005-0113-09," retrieved September 3, 2026, https://drugdashboards.com/drug/80005011309.

Free to cite with attribution — see how the data is put together.